144 related articles for article (PubMed ID: 23846919)
1. BRCA and pancreatic cancer.
Brennan GT; Relias V; Saif MW
JOP; 2013 Jul; 14(4):325-8. PubMed ID: 23846919
[TBL] [Abstract][Full Text] [Related]
2. BRCA and pancreatic cancer: selection of chemotherapy.
Kim R; Byer J; Saif MW
JOP; 2012 Mar; 13(2):180-1. PubMed ID: 22406596
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: BRCA mutation and personalized treatment.
Luo G; Lu Y; Jin K; Cheng H; Guo M; Liu Z; Long J; Liu C; Ni Q; Yu X
Expert Rev Anticancer Ther; 2015; 15(10):1223-31. PubMed ID: 26402249
[TBL] [Abstract][Full Text] [Related]
4. PARP-inhibitors in BRCA-associated pancreatic cancer.
Bhalla A; Saif MW
JOP; 2014 Jul; 15(4):340-3. PubMed ID: 25076338
[TBL] [Abstract][Full Text] [Related]
5. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
6. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
7.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
8. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
9. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
10. BRCA-associated pancreatic cancer: the evolving management.
Leung K; Saif MW
JOP; 2013 Mar; 14(2):149-51. PubMed ID: 23474559
[TBL] [Abstract][Full Text] [Related]
11. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping.
Sharma MB; Carus A; Sunde L; Hamilton-Dutoit S; Ladekarl M
Acta Oncol; 2016; 55(3):377-81. PubMed ID: 26004055
[No Abstract] [Full Text] [Related]
12. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
[TBL] [Abstract][Full Text] [Related]
13. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
14. BRCA-mutant pancreatic ductal adenocarcinoma.
Lai E; Ziranu P; Spanu D; Dubois M; Pretta A; Tolu S; Camera S; Liscia N; Mariani S; Persano M; Migliari M; Donisi C; Demurtas L; Pusceddu V; Puzzoni M; Scartozzi M
Br J Cancer; 2021 Nov; 125(10):1321-1332. PubMed ID: 34262146
[TBL] [Abstract][Full Text] [Related]
15. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Carnevale J; Ashworth A
J Clin Oncol; 2015 Oct; 33(28):3080-1. PubMed ID: 25987697
[No Abstract] [Full Text] [Related]
17. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
Vyas O; Leung K; Ledbetter L; Kaley K; Rodriguez T; Garcon MC; Saif MW
Anticancer Drugs; 2015 Feb; 26(2):224-6. PubMed ID: 25304989
[TBL] [Abstract][Full Text] [Related]
18. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
Sundararajan S; Ahmed A; Goodman OB
Clin Adv Hematol Oncol; 2011 Oct; 9(10):748-55. PubMed ID: 22252577
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
[TBL] [Abstract][Full Text] [Related]
20. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]